RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipi...

Bibliografski detalji
Glavni autori:	Fengxu Lv, Wentao Si, Xiaodan Xu, Xiaogang He, Ying Wang, Yetian Li, Feifei Li
Format:	Članak
Jezik:	English
Izdano:	Elsevier 2024-02-01
Serija:	Neoplasia: An International Journal for Oncology Research
Teme:	Triple negative breast cancer Chemoresistance Cancer stem cells RUNX2 TGF-β
Online pristup:	http://www.sciencedirect.com/science/article/pii/S1476558624000046

Slični predmeti

RUNX2 facilitates aggressiveness and chemoresistance of triple negative breast cancer cells via activating MMP1
od: Wentao Si, i dr.
Izdano: (2022-11-01)

RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer
od: Natalia B. Fernández, i dr.
Izdano: (2023-01-01)

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
od: Bradley A. Hancock, i dr.
Izdano: (2019-08-01)

Comprehensive Analysis of RUNX and TGF-β Mediated Regulation of Immune Cell Infiltration in Breast Cancer
od: Liang Gao, i dr.
Izdano: (2021-08-01)

TGF-β induced reprogramming and drug resistance in triple-negative breast cells
od: Guoyu Wu, i dr.
Izdano: (2022-04-01)

CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death
od: Alexander H. Chung, i dr.
Izdano: (2019-02-01)

DNA methylation affects metastasis of renal cancer and is associated with TGF-β/RUNX3 inhibition
od: Jianbo Zheng, i dr.
Izdano: (2018-04-01)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
od: Meng Wang, i dr.
Izdano: (2021-10-01)

Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers
od: Anuradha Illendula, i dr.
Izdano: (2016-06-01)

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
od: Margarite D. Matossian, i dr.
Izdano: (2019-03-01)

Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer
od: Adam Hermawan, i dr.
Izdano: (2019-12-01)

The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of Context
od: Adiba S. Khan, i dr.
Izdano: (2023-02-01)

Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer
od: Shen-Jun Yuan, i dr.
Izdano: (2019-10-01)

B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer
od: Ling Wang, i dr.
Izdano: (2018-07-01)

A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer
od: Hitesh Kumar, i dr.
Izdano: (2023-12-01)

miR-613 Suppresses Chemoresistance and Stemness in Triple-Negative Breast Cancer by Targeting FAM83A
od: Liu C, i dr.
Izdano: (2020-12-01)

A clinicopathologic study of triple negative breast cancer
od: Vandana L Gaopande, i dr.
Izdano: (2015-01-01)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
od: Nicholas R. Hum, i dr.
Izdano: (2022-07-01)

Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBC
od: Andrew Sulaiman, i dr.
Izdano: (2021-10-01)

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
od: Alaa M. Ghallab, i dr.
Izdano: (2022-04-01)

Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer
od: Lei Di, i dr.
Izdano: (2019-03-01)

TUFT1 promotes metastasis and chemoresistance in triple negative breast cancer through the TUFT1/Rab5/Rac1 pathway
od: Weiguang Liu, i dr.
Izdano: (2019-09-01)

RUNX regulated immune-associated genes predicts prognosis in breast cancer
od: Jingyue Fu, i dr.
Izdano: (2022-08-01)

M6A demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer
od: Xi Liu, i dr.
Izdano: (2024-02-01)

CD74-AKT Axis Is a Potential Therapeutic Target in Triple-Negative Breast Cancer
od: Jingchao Wang, i dr.
Izdano: (2024-06-01)

Role of eIF4A1 in triple‐negative breast cancer stem‐like cell‐mediated drug resistance
od: Dayanidhi Raman, i dr.
Izdano: (2022-12-01)

Cyclodextrin Diethyldithiocarbamate Copper II Inclusion Complexes: A Promising Chemotherapeutic Delivery System against Chemoresistant Triple Negative Breast Cancer Cell Lines
od: Ammar Said Suliman, i dr.
Izdano: (2021-01-01)

Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
od: Yen-Dun Tony Tzeng, i dr.
Izdano: (2018-11-01)

TUFT1 Promotes Triple Negative Breast Cancer Metastasis, Stemness, and Chemoresistance by Up-Regulating the Rac1/β-Catenin Pathway
od: Weiguang Liu, i dr.
Izdano: (2019-07-01)

Current approaches in treatment of triple-negative breast cancer
od: Hanan Ahmed Wahba, i dr.
Izdano: (2015-06-01)

Triple-Negative Breast Cancer Survival in Iranian Patients
od: Mahdi Aghili, i dr.
Izdano: (2013-08-01)

Platinum chemotherapy for early triple-negative breast cancer
od: Sofia RE. Mason, i dr.
Izdano: (2024-06-01)

Does triple negative breast cancer subtype carry poorer prognosis as compared to non-triple negative breast cancer lesion - A study from a tertiary hospital
od: Srijan Basu, i dr.
Izdano: (2023-11-01)

Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
od: Omran Saifi, i dr.
Izdano: (2022-04-01)

USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1
od: Yueh-Te Lin, i dr.
Izdano: (2022-10-01)

Immunotherapy Treatment for Triple Negative Breast Cancer
od: Elizabeth R. Berger, i dr.
Izdano: (2021-08-01)

Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
od: Magdalena Niedolistek, i dr.
Izdano: (2020-04-01)

Tissue Inhibitor of Metalloproteinases-1 Overexpression Mediates Chemoresistance in Triple-Negative Breast Cancer Cells
od: Lisa Agnello, i dr.
Izdano: (2023-07-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
od: Mohammed Amrallah A., i dr.
Izdano: (2021-05-01)

The Adipokine Visfatin Modulates Cancer Stem Cell Properties in Triple-Negative Breast Cancer
od: Yi-Fen Chiang, i dr.
Izdano: (2023-01-01)